Oxford Nanopore signs CRISPR licence
20-09-2019
ERS extends CRISPR influence with two licensing deals
20-09-2018
Pacific Biosciences and Oxford Nanopore settle patent claims
09-05-2018
Xesai / iStockphoto.com
Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Oxford Nanopore Technologies, Amgen, investment, gene sequencing, DNA, RNA
